GlassScriptPhysician profile
Haroon Chaudhry
NPI 1245432392
$17,594.21
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $141 · 2021: $584 · 2022: $932 · 2023: $1,337 · 2024: $1,867 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,246 · Food and Beverage: $5,140 · Travel and Lodging: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,245.77 |
| Food and Beverage | $5,140.32 |
| Travel and Lodging | $1,271.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12,215.89 | 2022-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,083.12 | 2022-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $845.59 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $631.48 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $587.49 | 2023-2025 | Izervay |
| Abbvie INC. | $391.89 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $332.41 | 2020-2023 | |
| Alcon Vision LLC | $257.16 | 2021-2024 | Ngenuity, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $241.26 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $212.40 | 2024-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $152.38 | 2021 | |
| Astellas US LLC | $135.72 | 2024 | Izervay |
| Carl Zeiss Meditec USA, INC. | $135.08 | 2021 | |
| Dutch Ophthalmic, USA | $124.78 | 2024-2025 | Eva, Combined Machine, Tissueblue |
| Bausch & Lomb Americas INC. | $118.13 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $79.88 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Harrow Eye, LLC | $20.16 | 2025 | Iheezo |
| Horizon Therapeutics Plc | $16.71 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.